Positive News SentimentPositive NewsNASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis $0.65 +0.01 (+0.95%) (As of 08/30/2024 08:54 PM ET) Add Compare Share Share Today's Range$0.62▼$0.6650-Day Range$0.53▼$0.8752-Week Range$0.51▼$2.53Volume167,100 shsAverage Volume358,447 shsMarket Capitalization$51.71 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioLineRx alerts: Email Address BioLineRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,146.3% Upside$21.00 Price TargetShort InterestHealthy0.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.87Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.25) to ($0.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 starsMedical Sector417th out of 933 stocksPharmaceutical Preparations Industry194th out of 440 stocks 3.5 Analyst's Opinion Consensus RatingBioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioLineRx has received no research coverage in the past 90 days.Read more about BioLineRx's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.33% of the outstanding shares of BioLineRx have been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently decreased by 3.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLRX. Previous Next 4.4 News and Social Media Coverage News SentimentBioLineRx has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioLineRx this week, compared to 1 article on an average week.Search Interest2 people have searched for BLRX on MarketBeat in the last 30 days. MarketBeat Follows8 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BioLineRx is held by insiders.Percentage Held by InstitutionsOnly 1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($0.25) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about BioLineRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About BioLineRx Stock (NASDAQ:BLRX)BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Read More BLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLRX Stock News HeadlinesAugust 20, 2024 | finance.yahoo.comBLRX: On Track for 60% Formulary PlacementAugust 19, 2024 | investing.comEarnings call: BioLineRx beats Q2 goals with strong APHEXDA demandSeptember 3, 2024 | Mode Mobile (Ad)First Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 16, 2024 | msn.comBioLineRx Ltd. (NASDAQ:BLRX) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comBioLineRx Ltd. (BLRX) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | prnewswire.comBioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio UpdatesAugust 8, 2024 | prnewswire.comBioLineRx to Report Second Quarter 2024 Results on August 15, 2024July 21, 2024 | finance.yahoo.comBioLineRx Ltd. (BLRX)September 3, 2024 | Mode Mobile (Ad)First Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.June 5, 2024 | investorplace.comMillionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025May 30, 2024 | prnewswire.comBioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)May 29, 2024 | msn.comBioLineRx Ltd. (NASDAQ:BLRX) Q1 2024 Earnings Call TranscriptMay 28, 2024 | prnewswire.comBioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio UpdatesMay 24, 2024 | prnewswire.comBioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual MeetingMay 22, 2024 | finance.yahoo.comBioLineRx to Report First Quarter 2024 Results on May 28, 2024May 22, 2024 | prnewswire.comBioLineRx to Report First Quarter 2024 Results on May 28, 2024May 17, 2024 | prnewswire.comBioLineRx Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 6, 2024 | prnewswire.comBioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024See More Headlines Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/28/2024Today9/02/2024Next Earnings (Estimated)11/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLRX CUSIPN/A CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+3,146.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,610,000.00 Net MarginsN/A Pretax Margin-176.67% Return on Equity-225.62% Return on Assets-51.71% Debt Debt-to-Equity Ratio1.34 Current Ratio1.61 Quick Ratio1.49 Sales & Book Value Annual Sales$17.05 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book3.81Miscellaneous Outstanding Shares79,939,000Free Float79,060,000Market Cap$51.71 million OptionableOptionable Beta1.52 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Philip A. Serlin CPA (Age 64)M.B.A., CPA, MBA, Chief Executive Officer Comp: $598kMs. Mali Zeevi CPA (Age 48)CPA, Chief Financial Officer Comp: $374kDr. Ella Sorani Ph.D. (Age 56)Chief Development Officer Comp: $452kMs. Holly W. May M.B.A. (Age 62)President of BioLineRx USA Comp: $710kMr. John LaceyHead of Corporate Communications & Investor RelationsMs. Tsipi Keren-Lehrer B.Sc.L.L.B., Head of BD & Strategic AdvisorMr. Raziel FriedTreasurer & Budgetary Control DirectorMore ExecutivesKey CompetitorsPyxis OncologyNASDAQ:PYXSTenaya TherapeuticsNASDAQ:TNYAMacroGenicsNASDAQ:MGNXScilexNASDAQ:SCLXAtai Life SciencesNASDAQ:ATAIView All CompetitorsInstitutional OwnershipPVG Asset Management CorpBought 123,580 shares on 8/22/2024Ownership: 0.155%CVI Holdings LLCBought 815,683 shares on 8/15/2024Ownership: 1.020%View All Institutional Transactions BLRX Stock Analysis - Frequently Asked Questions How have BLRX shares performed this year? BioLineRx's stock was trading at $1.57 at the beginning of 2024. Since then, BLRX shares have decreased by 58.8% and is now trading at $0.6469. View the best growth stocks for 2024 here. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) announced its quarterly earnings results on Tuesday, May, 28th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.28. The biotechnology company had revenue of $6.86 million for the quarter, compared to analyst estimates of $0.34 million. Who are BioLineRx's major shareholders? Top institutional investors of BioLineRx include CVI Holdings LLC (1.02%) and PVG Asset Management Corp (0.15%). How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI). This page (NASDAQ:BLRX) was last updated on 9/3/2024 by MarketBeat.com Staff From Our PartnersFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredFREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportun...Monument Traders Alliance | SponsoredAmazon coin set to soar 25X – starting September 23rdChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredKamala? Trump? _______? Think again. This play has delivered an annualized average gain of nearly 50% in just three months time… before every singl...The Freeport Society | SponsoredBiden’s Big Fix America's Next Nightmare (has nothing to do with November) Roosevelt failed to make it work during World W...Stansberry Research | SponsoredForget polls, focus on these 5 tickersWith all the geopolitical tensions in the world… all the inflation… all the expectations of a new round of Fed...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLRX Stock Alerts